Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-05

Study Completion Date

2018-06-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to collect emission spectra of normal tissue, pigmented normal lesion, benign lesion, SCC, BCC and melanoma to construct the database and validate the classifying algorithm.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MicroRNA Expression and Function in Cutaneous Malignant Melanoma

NCT00536029

Melanoma

COMPLETED

Melanoma Detection by Oblique-Incidence Optical Spectroscopy

NCT00526032

Skin Cancer

COMPLETED

Optical Spectroscopy for Cutaneous Cancer

NCT02522793

Suspicious Skin Lesion(s) Requiring a Biopsy

COMPLETED

Stratification of Cutaneous Squamous Cell Carcinomas According to Its Transcriptomic, Metabolic and Inflammatory Characteristics

NCT06476964

Skin Cancer

RECRUITING NA

A Prospective Multicenter Sample Collection Study Using Non-invasive Methods to Investigate Mutation Burden in Non-lesional Facial Skin of Patients With a Hx of Skin Cancer

NCT05602337

Melanoma and Other Malignant Neoplasms of Skin

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Speclipse Spectra-Scope consists of the light collection module and the spectral analysis module. The light collection module is attached to the handpiece of short pulse (a few nanoseconds) Nd:YAG (neodymium-doped yttrium aluminium garnet) commercial cosmetic laser, and the analysis module is placed on the laser. When Nd:YAG laser is irradiated onto the skin lesion, the laser ablates a trace amount of tissue, producing micro plasma. The emitted light from the micro plasma is analysed spectrally to determine the elemental and molecular information from the tissue in real time. No calibration of the Spectra-Scope is required.

Before the skin is irradiated with the laser, select the age, sex and the position of the target skin lesion and put the patient number of the day on the software panel of laptop which is connected to the device. Prior to sampling, the skin site must be wiped with ethanol and allowed to air dry. When the laser is irradiated, the emission spectra of tissue is automatically generated from the spectrometer inside the device and simultaneously displayed on the monitor, and stored in the laptop. The spectral data stored in the laptop is wirelessly accessible using Google drive.

An algorithm then determines whether the skin is from a normal, pigmented normal, benign, squamous cell carcinoma (SCC), basal cell carcinoma (BCC) or melanoma based on the spectral 'signature'. These algorithms have been determined during clinical ex-vivo and in-vivo studies performed in Korea. The purpose of this study is to collect tissue emission spectra of Australian patients and to further refine the algorithms, and to confirm the appropriate spectra for 'normal', 'benign', 'melanoma', 'SCC', and 'BCC'.

Each potential skin cancer site, which has previously been identified as requiring biopsy, is assessed using five laser shots that last approximately 10 milliseconds per shot and measurement. The laser shots are made before the scheduled biopsy.

Some of the potential skin cancer sites will be labelled as cancers ('melanoma', 'SCC' or 'BCC') from the biopsy result, and some of the potential skin cancer site will be labelled as 'benign' (control group 1) from the biopsy result.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Measurement using Spectra-Scope

Short pulsed Nd:YAG laser irradiation onto the skin lesion / measurement with Spectra-Scope

Group Type EXPERIMENTAL

Spectra-Scope

Intervention Type DEVICE

The Spectra-Scope consists of the light collection module and the spectral analysis module.

The light collection module is attached to the handpiece of short pulse Nd:YAG laser, and the analysis module is placed on the laser.

Each potential skin cancer site, which has previously been identified as requiring biopsy, should be assessed using five laser shots that last approximately 10 milliseconds per shot and measurement. The laser shots must be made before the scheduled biopsy.

All potentially cancerous lesions (or lesions that would usually undergo complete biopsy of the lesion or require follow up within three months) should be sampled. The Spectra-Scope will not provide a diagnosis at the time of sampling. Sites should record the spectra reported for each laser shot in the CRF.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spectra-Scope

The Spectra-Scope consists of the light collection module and the spectral analysis module.

The light collection module is attached to the handpiece of short pulse Nd:YAG laser, and the analysis module is placed on the laser.

Each potential skin cancer site, which has previously been identified as requiring biopsy, should be assessed using five laser shots that last approximately 10 milliseconds per shot and measurement. The laser shots must be made before the scheduled biopsy.

All potentially cancerous lesions (or lesions that would usually undergo complete biopsy of the lesion or require follow up within three months) should be sampled. The Spectra-Scope will not provide a diagnosis at the time of sampling. Sites should record the spectra reported for each laser shot in the CRF.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Be aged 18 years or over;
2. Have at least one suspicious lesion that:

1. Is required to be biopsied for assessment of skin cancer (as assessed by at least one dermatologist);
2. Has a diameter of more than 2 mm but less than 22 mm;
3. Is accessible to the Spectra-Scope device;
3. Provide written informed consent.

Exclusion Criteria

1. Have a known allergy to ethanol;
2. Have a lesion that:

1. Has previously been biopsied, excised or traumatised;
2. Is not intact;
3. Is within 1 cm of the eye;
4. Is on a mucosal surface (lips, genitals);
5. Is on palmar hands;
6. Is on palmar feet;
7. Is on or under nails;
8. Is located on or in an area of visible scarring;
9. Contains foreign matter (tattoo, splinter, marker)
3. Have an active infection;
4. Have an open lesion sampled;
5. Have an autoimmune disease such as lupus or scleroderma vitiligo.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes